New License Agreement Announced for Next-Generation Base … – BioPharm International

The pin-point system is completely modular, allowing for different components to be selected for optimal performance specific to the gene targets.

Revvity, Inc. announced on May 18, 2023, a new license agreement with AstraZeneca for the technology underlying technology in its Pin-point base editing system, which is a next-generation modular gene editing platform with a strong safety profile.

The Pin-point system and the base editing technology is defined as allowing highly efficient, precise single and multi-gene editing without unintended impact on cell viability or functionality. According to the press release, this newer editing system uses a modified Cas enzyme that only marks one strand of the DNA, which allows for a more controlled approach to gene distribution and base correction.

Different from other editing systems, the pin-point system is completely modular, allowing for different components to be selected for optimal performance specific to the gene targets. Additionally, Revvity has also developed a novel proprietary method to leverage the base editing mechanism to insert genes, like creating an allogeneic CAR-T cell therapy by knocking in a CAR while knocking out immune markers at the same time, according to the press release.

Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, impact patient lives, said Alan Fletcher, PhD, senior vice president, Life Sciences at Revvity, in a press release. In that vein, we are delighted to announce this non-exclusive agreement with AstraZeneca to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.

Source: Revvity

See the original post here:

New License Agreement Announced for Next-Generation Base ... - BioPharm International